NSEI:CADILAHC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. More Details


Snowflake Analysis

Established dividend payer with adequate balance sheet.


Similar Companies

Share Price & News

How has Cadila Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CADILAHC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.3%

CADILAHC

-1.0%

IN Pharmaceuticals

-0.4%

IN Market


1 Year Return

74.1%

CADILAHC

50.1%

IN Pharmaceuticals

2.3%

IN Market

Return vs Industry: CADILAHC exceeded the Indian Pharmaceuticals industry which returned 50.1% over the past year.

Return vs Market: CADILAHC exceeded the Indian Market which returned 2.3% over the past year.


Shareholder returns

CADILAHCIndustryMarket
7 Day2.3%-1.0%-0.4%
30 Day8.3%-0.3%3.3%
90 Day17.2%12.8%6.7%
1 Year76.2%74.1%52.1%50.1%4.0%2.3%
3 Year-8.8%-12.1%29.8%26.3%0.6%-4.1%
5 Year7.8%2.1%0.5%-3.1%42.3%31.8%

Price Volatility Vs. Market

How volatile is Cadila Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cadila Healthcare undervalued compared to its fair value and its price relative to the market?

32.86x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CADILAHC (₹425.65) is trading above our estimate of fair value (₹209.34)

Significantly Below Fair Value: CADILAHC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CADILAHC is poor value based on its PE Ratio (32.9x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: CADILAHC is poor value based on its PE Ratio (32.9x) compared to the Indian market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: CADILAHC is poor value based on its PEG Ratio (3x)


Price to Book Ratio

PB vs Industry: CADILAHC is overvalued based on its PB Ratio (4.2x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Cadila Healthcare forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?

11.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CADILAHC's forecast earnings growth (11% per year) is above the savings rate (7.2%).

Earnings vs Market: CADILAHC's earnings (11% per year) are forecast to grow slower than the Indian market (25.5% per year).

High Growth Earnings: CADILAHC's earnings are forecast to grow, but not significantly.

Revenue vs Market: CADILAHC's revenue (7.5% per year) is forecast to grow slower than the Indian market (11.5% per year).

High Growth Revenue: CADILAHC's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CADILAHC's Return on Equity is forecast to be low in 3 years time (15.2%).


Next Steps

Past Performance

How has Cadila Healthcare performed over the past 5 years?

1.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CADILAHC has high quality earnings.

Growing Profit Margin: CADILAHC's current net profit margins (9.2%) are lower than last year (12.3%).


Past Earnings Growth Analysis

Earnings Trend: CADILAHC's earnings have grown by 1.6% per year over the past 5 years.

Accelerating Growth: CADILAHC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CADILAHC had negative earnings growth (-21.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: CADILAHC's Return on Equity (11.7%) is considered low.


Next Steps

Financial Health

How is Cadila Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: CADILAHC's short term assets (₹87.2B) exceed its short term liabilities (₹82.7B).

Long Term Liabilities: CADILAHC's short term assets (₹87.2B) exceed its long term liabilities (₹37.1B).


Debt to Equity History and Analysis

Debt Level: CADILAHC's debt to equity ratio (68.2%) is considered high.

Reducing Debt: CADILAHC's debt to equity ratio has increased from 59.6% to 68.2% over the past 5 years.

Debt Coverage: CADILAHC's debt is well covered by operating cash flow (31.4%).

Interest Coverage: CADILAHC's interest payments on its debt are well covered by EBIT (8.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Cadila Healthcare current dividend yield, its reliability and sustainability?

0.82%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CADILAHC's dividend (0.82%) is higher than the bottom 25% of dividend payers in the Indian market (0.56%).

High Dividend: CADILAHC's dividend (0.82%) is low compared to the top 25% of dividend payers in the Indian market (2.3%).


Stability and Growth of Payments

Stable Dividend: CADILAHC's dividends per share have been stable in the past 10 years.

Growing Dividend: CADILAHC's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (27%), CADILAHC's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CADILAHC's dividends in 3 years are forecast to be well covered by earnings (19.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average board tenure


CEO

Sharvil Patel (41 yo)

3.5yrs

Tenure

₹250,000,000

Compensation

Dr. Sharvil Pankajbhai Patel has been Managing Director of Cadila Healthcare Limited since April 1, 2017 and previously served as its Joint Managing Director from March 15, 2017 to April 1, 2017. Dr. Patel ...


CEO Compensation Analysis

Compensation vs Market: Sharvil's total compensation ($USD3.39M) is above average for companies of similar size in the Indian market ($USD1.04M).

Compensation vs Earnings: Sharvil's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Sharvil Patel
MD & Executive Director3.5yrs₹250.00m0.0015%
₹ 6.4m
Ganesh Nayak
COO & Executive Director3.25yrs₹278.94m0.025%
₹ 107.1m
Pankaj Patel
Non-Executive Chairmanno data₹1.70m74.87%
₹ 326.8b
Apurva Diwanji
Independent Director4.42yrs₹4.15mno data
Mukesh Patel
Non-Executive Director23.17yrs₹4.65m0.0012%
₹ 5.1m
Bhadresh Shah
Independent Director1.83yrs₹3.15mno data
Kapil Dhingra
Member of Scientific Advisory Boardno datano datano data
Dharmishtaben Raval
Non-Executive Independent Director6.42yrs₹4.55mno data
Nitin Desai
Non-Executive Independent Director9.42yrs₹4.25m0.043%
₹ 188.4m
John Amatruda
Member of Scientific Advisory Boardno datano datano data

6.4yrs

Average Tenure

65.5yo

Average Age

Experienced Board: CADILAHC's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cadila Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cadila Healthcare Limited
  • Ticker: CADILAHC
  • Exchange: NSEI
  • Founded: 1952
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹436.473b
  • Shares outstanding: 1.02b
  • Website: https://www.zyduscadila.com

Number of Employees


Location

  • Cadila Healthcare Limited
  • Zydus Corporate Park
  • Scheme No. 63
  • Ahmedabad
  • Gujarat
  • 382481
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532321BSE (Mumbai Stock Exchange)YesEquity SharesININRApr 2000
CADILAHCNSEI (National Stock Exchange of India)YesEquity SharesININRApr 2000

Biography

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. It offers finished dosag ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 12:39
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.